# US 2021/0260098 A1 · Cell protective methods and compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0260098 A1
- Document ID: US20210260098A1
- Status: Published application
- Kind: A1
- Application number: 17/254,145
- Filed: 2019-06-19
- Published: 2021-08-26
- Earliest claimed: 2018-06-20
- Assignees: The University of North Carolina at Chapel Hill
- Applicants: The University of North Carolina at Chapel Hill
- Inventors: Jian Liu; Jine Li; Guowei Su; Rafal Pawlinski; Erica Sparkenbaugh
- Web page: https://patentgrep.com/patent/US20210260098A1

## CPC

- A61K 31/737: Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate (A61K31/727 takes precedence)
- A61P 31/04: Antibacterial agents
- A61P 39/02: Antidotes
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Chondroitin sulfate compounds comprising chondroitin sulfate backbone 19 mer, CS-A 19 mer, CS-C 19 mer, CS-E 19 mer, C8 backbone 13 mer, C8-A 13 mer, CS-C 13 mer, CS-E 13 mer and/or combinations thereof are provided. Methods of treating histone toxicity in a subject are provided, the methods including administering to a subject a chondroitin sulfate compound to treat the histone toxicity in the subject. Pharmaceutical compositions for use in treating histone toxicity and/or sepsis are provided. Methods of treating sepsis in a subject are provided, the methods including administering to a subject a chondroitin sulfate compound to treat the sepsis in the subject.

## Claims

### Claim 1

A method of treating histone toxicity in a subject, the method comprising:
providing a subject in need of histone toxicity treatment; and
administering to the subject a chondroitin sulfate compound, wherein the histone toxicity in the subject is treated.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject is suffering from sepsis.

### Claim 3 (depends on 1, 2)

The method of claim 1 or claim 2, wherein the subject is a human subject.

### Claim 4

The method of any of the above claims, wherein the chondroitin sulfate compound comprises a CS backbone, CS-A, CS-E, CS-C and/or combinations thereof.

### Claim 5

The method of any of the above claims, wherein the chondroitin sulfate compound comprises chondroitin sulfate backbone 19 mer, CS-A 19 mer, CS-C 19 mer, CS-E 19 mer, CS backbone 13 mer, CS-A 13 mer, CS-C 13 mer, CS-E 13 mer and/or combinations thereof.

### Claim 6

The method of any of the above claims, wherein the chondroitin sulfate compound comprises one or more of the following structures:
wherein R is selected from the group consisting of —H, alkyl (such as but not limited to —CH3 or —CH2CH3), substituted alkyl, aryl, and substituted aryl (such as but not limited to a p-nitrophenyl group), wherein n is 1, 2, 3, 4, 5, 6, 7 or 8.

### Claim 7

The method of any of the above claims, wherein the chondroitin sulfate compound is administered as part of a pharmaceutical composition.

### Claim 8

The method of any of the above claims, wherein the pharmaceutical composition comprises a CS compound and a pharmaceutically acceptable carrier or adjuvant for administration of the CS.

### Claim 9

A pharmaceutical composition for use in treating histone toxicity and/or sepsis, the composition comprising one or more chondroitin sulfate compounds and a pharmaceutically acceptable carrier.

### Claim 10 (depends on 9)

The pharmaceutical composition of claim 9, wherein the chondroitin sulfate compound comprises a CS backbone, CS-A, CS-E, CS-C and/or combinations thereof.

### Claim 11 (depends on 9, 10)

The pharmaceutical composition of claim 9 or claim 10, wherein the chondroitin sulfate compound comprises chondroitin sulfate backbone 19 mer, CS-A 19 mer, CS-C 19 mer, CS-E 19 mer, CS backbone 13 mer, CS-A 13 mer, CS-C 13 mer, CS-E 13 mer and/or combinations thereof.

### Claim 12 (depends on 9, 10, 11)

The pharmaceutical composition of any one of claims 9-11, wherein the chondroitin sulfate compound comprises one or more of the following structures:
wherein R is selected from the group consisting of —H, alkyl (such as but not limited to —CH3 or —CH2CH3), substituted alkyl, aryl, and substituted aryl (such as but not limited to a p-nitrophenyl group), wherein n is 1, 2, 3, 4, 5, 6, 7 or 8.

### Claim 13

A method of treating sepsis in a subject, the method comprising:
providing a subject in need of sepsis treatment; and
administering to the subject a chondroitin sulfate compound, wherein the sepsis in the subject is treated.

### Claim 14 (depends on 13)

The method of claim 13, wherein the subject is a human subject.

### Claim 15

The method of any of the above claims, wherein the chondroitin sulfate compound comprises a CS backbone, CS-A, CS-E, CS-C and/or combinations thereof.

### Claim 16

The method of any of the above claims, wherein the chondroitin sulfate compound comprises chondroitin sulfate backbone 19 mer, CS-A 19 mer, CS-C 19 mer, CS-E 19 mer, CS backbone 13 mer, CS-A 13 mer, CS-C 13 mer, CS-E 13 mer and/or combinations thereof.

### Claim 17

The method of any of the above claims, wherein the chondroitin sulfate compound comprises one or more of the following structures:
wherein R is selected from the group consisting of —H, alkyl (such as but not limited to —CH3 or —CH2CH3), substituted alkyl, aryl, and substituted aryl (such as but not limited to a p-nitrophenyl group), wherein n is 1, 2, 3, 4, 5, 6, 7 or 8.

### Claim 18

The method of any of the above claims, wherein the chondroitin sulfate compound is administered as part of a pharmaceutical composition.

### Claim 19

The method of any of the above claims, wherein the pharmaceutical composition comprises a CS compound and a pharmaceutically acceptable carrier or adjuvant for administration of the CS.
